{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:44:46Z","timestamp":1792683886538,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"am","delay-in-days":344,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.phrs.2022.106329","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T12:05:08Z","timestamp":1656331508000},"page":"106329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Locoregional delivery of CAR-T cells in the clinic"],"prefix":"10.1016","volume":"182","author":[{"given":"Sharon M.","family":"Sagnella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dannel","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"van Zandwijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.J.","family":"Rasko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.phrs.2022.106329_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3390\/cancers12010125","article-title":"Advancing CAR T-cell therapy for solid tumors: lessons learned from lymphoma treatment","volume":"12","author":"Titov","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.phrs.2022.106329_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.phrs.2022.106329_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40364-021-00264-1","article-title":"Anti-Mesothelin CAR T cell therapy for malignant mesothelioma","volume":"9","author":"Castelletti","year":"2021","journal-title":"Biomark. Res."},{"issue":"11","key":"10.1016\/j.phrs.2022.106329_bib4","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T cell therapy for solid tumors: bright future or dark reality?","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2022.106329_bib5","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/icb.2016.128","article-title":"CAR T-cell therapy of solid tumors","volume":"95","author":"Yong","year":"2017","journal-title":"Immunol. Cell Biol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106329_bib6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41392-020-00256-x","article-title":"The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma","volume":"5","author":"Wei","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.phrs.2022.106329_bib7","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.3389\/fimmu.2018.02166","article-title":"The potential of CAR T cell therapy in pancreatic cancer","volume":"9","author":"Akce","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2022.106329_bib8","doi-asserted-by":"crossref","first-page":"3425291","DOI":"10.1155\/2019\/3425291","article-title":"Efficiency of CAR-T therapy for treatment of solid tumor in clinical trials: a meta-analysis","volume":"2019","author":"Hou","year":"2019","journal-title":"Dis. Markers"},{"key":"10.1016\/j.phrs.2022.106329_bib9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.phrs.2022.106329_bib10","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11427-016-5027-4","article-title":"Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors","volume":"59","author":"Zhang","year":"2016","journal-title":"Sci. China Life Sci."},{"issue":"9","key":"10.1016\/j.phrs.2022.106329_bib11","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.phrs.2022.106329_bib12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/cancers9070092","article-title":"Regional delivery of chimeric antigen receptor (CAR) T-cells for cancer therapy","volume":"9","author":"Sridhar","year":"2017","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.phrs.2022.106329_bib13","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1023\/A:1008335318764","article-title":"Locoregional immunotherapy in cancer patients: review of clinical studies","volume":"11","author":"van Herpen","year":"2000","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.phrs.2022.106329_bib14","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s00262-016-1895-5","article-title":"The growing world of CAR T cell trials: a systematic review","volume":"65","author":"Holzinger","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.phrs.2022.106329_bib15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/vaccines8020191","article-title":"The impact of locoregional treatment on response to nivolumab in advanced platinum refractory head and neck cancer: the need trial","volume":"8","author":"Botticelli","year":"2020","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.phrs.2022.106329_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11912-003-0084-9","article-title":"Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis","volume":"5","author":"Berg","year":"2003","journal-title":"Curr. Oncol. Rep."},{"issue":"42","key":"10.1016\/j.phrs.2022.106329_bib17","doi-asserted-by":"crossref","first-page":"73312","DOI":"10.18632\/oncotarget.20272","article-title":"Leptomeningeal disease: current diagnostic and therapeutic strategies","volume":"8","author":"Nayar","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.phrs.2022.106329_bib18","article-title":"Ommaya reservoir insertion: a technical note","volume":"12","author":"Magill","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.phrs.2022.106329_bib19","article-title":"Intracerebroventricular delivery as a safe, long-term route of administration","author":"Cohen-Pfeffer","year":"2016","journal-title":"Pediatr. Neurol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106329_bib20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1023\/A:1023309927635","article-title":"Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times","volume":"62","author":"Goetz","year":"2003","journal-title":"J. Neuro-Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2022.106329_bib21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/jjco\/hye055","article-title":"Intracavitary chemotherapy with 5-fluoro-2\u2019-deoxyuridine (FdUrd) in malignant brain tumors","volume":"31","author":"Nakagawa","year":"2001","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106329_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201801391","article-title":"Designing next\u2010generation local drug delivery vehicles for glioblastoma adjuvant chemotherapy: lessons from the clinic","volume":"8","author":"Tabet","year":"2019","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.phrs.2022.106329_bib23","doi-asserted-by":"crossref","first-page":"11483","DOI":"10.1038\/srep11483","article-title":"CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells","volume":"5","author":"Han","year":"2015","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.phrs.2022.106329_bib24","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMc1704610","article-title":"Anti-CD19 CAR T cells in CNS diffuse large-b-cell lymphoma","volume":"377","author":"Abramson","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.phrs.2022.106329_bib25","doi-asserted-by":"crossref","first-page":"E3529","DOI":"10.1073\/pnas.1601012113","article-title":"Diversity and divergence of the glioma-infiltrating T-cell receptor repertoire","volume":"113","author":"Sims","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"Suppl. 15","key":"10.1016\/j.phrs.2022.106329_bib26","article-title":"A phase 1 study to evaluate chimeric antigen receptor (CAR) T cells incorporating a chlorotoxin tumor-targeting domain for patients with MMP2+ Recurrent or progressive glioblastoma (NCT04214392)","volume":"39","author":"Badie","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.phrs.2022.106329_bib27","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.phrs.2022.106329_bib28","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+ T Cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2022.106329_bib29","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.3389\/fimmu.2019.02683","article-title":"CAR-engineered NK cells for the treatment of glioblastoma: turning innate effectors into precision tools for cancer immunotherapy","volume":"10","author":"Burger","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2022.106329_bib30","doi-asserted-by":"crossref","first-page":"669071","DOI":"10.3389\/fonc.2021.669071","article-title":"Case report: prolonged survival following EGFRvIII CAR T cell treatment for recurrent glioblastoma","volume":"11","author":"Durgin","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2022.106329_bib31","doi-asserted-by":"crossref","unstructured":"V.D. Jonsson, R.H. Ng, N. Dullerud, R.A. Wong, J. Hibbard, D. Wang, B. Aguilar, R. Starr, L. Weng, D. Alizadeh, S.J. Forman, B. Badie, Brown C.E. CAR T Cell Therapy Drives Endogenous Locoregional T Cell Dynamics in A Responding Patient with Glioblastoma, bioRxiv, 2021.","DOI":"10.1101\/2021.09.22.460392"},{"issue":"6","key":"10.1016\/j.phrs.2022.106329_bib32","doi-asserted-by":"crossref","first-page":"e1137","DOI":"10.1002\/cti2.1137","article-title":"Bioactivity and safety of B7-H3-targeted chimeric antigen receptor T cells against anaplastic meningioma","volume":"9","author":"Tang","year":"2020","journal-title":"Clin. Transl. Immunol."},{"issue":"9","key":"10.1016\/j.phrs.2022.106329_bib33","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis","volume":"1544\u20131552","author":"Vitanza","year":"2021","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.phrs.2022.106329_bib34","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s12094-018-1831-6","article-title":"From imaging to biology of glioblastoma: new clinical oncology perspectives to the problem of local recurrence","volume":"20","author":"Zygogianni","year":"2018","journal-title":"Clin. Transl. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106329_bib35","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4103\/bc.bc_30_21","article-title":"The entity of the trapped fourth ventricle: A review of its history, pathophysiology, and treatment options","volume":"7","author":"Panagopoulos","year":"2021","journal-title":"Brain Circ."},{"issue":"4","key":"10.1016\/j.phrs.2022.106329_bib36","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00381-015-2969-y","article-title":"Ventricular access device placement in the fourth ventricle to treat malignant fourth ventricle brain tumors: technical note","volume":"32","author":"Sandberg","year":"2016","journal-title":"Childs Nerv. Syst."},{"issue":"6","key":"10.1016\/j.phrs.2022.106329_bib37","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/neuros\/nyaa584","article-title":"Chimeric antigen receptor T-cell therapy: updates in glioblastoma treatment","volume":"88","author":"Feldman","year":"2021","journal-title":"Neurosurgery"},{"key":"10.1016\/j.phrs.2022.106329_bib38","article-title":"Off-the-shelf, steroid resistant, IL13Ralpha2-specific CAR T cells for treatment of glioblastoma","author":"Brown","year":"2022","journal-title":"NeuroOncology"},{"issue":"1","key":"10.1016\/j.phrs.2022.106329_bib39","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12967-018-1746-6","article-title":"Identification of a novel role of IL-13Ralpha2 in human glioblastoma multiforme: interleukin-13 mediates signal transduction through AP-1 pathway","volume":"16","author":"Bhardwaj","year":"2018","journal-title":"J. Transl. Med."},{"issue":"8","key":"10.1016\/j.phrs.2022.106329_bib40","first-page":"4702","article-title":"IL13RA2 is overexpressed in malignant gliomas and related to clinical outcome of patients","volume":"12","author":"Zeng","year":"2020","journal-title":"Am. J. Transl. Res."},{"issue":"1","key":"10.1016\/j.phrs.2022.106329_bib41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/ncponc1278","article-title":"Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma","volume":"6","author":"Yaghoubi","year":"2009","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.phrs.2022.106329_bib42","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.omto.2019.07.002","article-title":"B7-H3 as a Novel CAR-T therapeutic target for glioblastoma","volume":"14","author":"Tang","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2022.106329_bib43","article-title":"IMMU-11. Clinical updates and correlative findings from the first patient with DIPG treated with intracranial CAR T cells","volume":"23","author":"Vitanza","year":"2021","journal-title":"Neuro-Oncology"},{"issue":"20","key":"10.1016\/j.phrs.2022.106329_bib44","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/bloodadvances.2020004106","article-title":"CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma","volume":"5","author":"Siddiqi","year":"2021","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.phrs.2022.106329_bib45","first-page":"107","article-title":"Studies on the blood supply of tumors in man. III. Vascular patterns of the liver by hepatic arteriography in vivo","volume":"12","author":"Bierman","year":"1951","journal-title":"J. Natl. Cancer Inst."},{"issue":"21","key":"10.1016\/j.phrs.2022.106329_bib46","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1200\/JCO.2008.20.1301","article-title":"Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma","volume":"27","author":"Kemeny","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.phrs.2022.106329_bib47","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.phrs.2022.106329_bib48","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/cgt.2014.50","article-title":"Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases","volume":"21","author":"Saied","year":"2014","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.phrs.2022.106329_bib49","series-title":"Induction Chemotherapy: Systemic and Locoregional","first-page":"253","article-title":"Interventional radiological procedures for port-catheter implantation","author":"Arai","year":"2016"},{"key":"10.1016\/j.phrs.2022.106329_bib50","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.omto.2022.01.010","article-title":"The next wave of cellular immunotherapies in pancreatic cancer","volume":"24","author":"Yeo","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.phrs.2022.106329_bib51","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3389\/fonc.2019.00148","article-title":"Systematic review of the prognostic role of the immune system after surgery of colorectal liver metastases","volume":"9","author":"Hof","year":"2019","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106329_bib52","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/cgt.2016.54","article-title":"Immunosuppression in liver tumors: opening the portal to effective immunotherapy","volume":"24","author":"Guha","year":"2017","journal-title":"Cancer Gene Ther."},{"issue":"2","key":"10.1016\/j.phrs.2022.106329_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001097","article-title":"HITM-SURE: hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery","volume":"8","author":"Katz","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"Suppl. 13","key":"10.1016\/j.phrs.2022.106329_bib54","article-title":"Abstract CT109: HITM-SIR: phase Ib trial of CAR-T hepatic artery infusions and selective internal radiation therapy for liver metastases","volume":"77","author":"Katz","year":"2017","journal-title":"Cancer Res."},{"issue":"43","key":"10.1016\/j.phrs.2022.106329_bib55","doi-asserted-by":"crossref","first-page":"69916","DOI":"10.18632\/oncotarget.12066","article-title":"Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma","volume":"7","author":"Kaseb","year":"2016","journal-title":"Oncotarget"},{"issue":"Suppl. 13","key":"10.1016\/j.phrs.2022.106329_bib56","article-title":"Abstract 3766: MG7-car, a first-in-class T-cell therapy for gastric cancer","volume":"77","author":"Yuan","year":"2017","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.phrs.2022.106329_bib57","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1200\/JCO.2005.05.2456","article-title":"Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment","volume":"24","author":"Markman","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106329_bib58","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.phrs.2022.106329_bib59","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/1758834010361333","article-title":"Review: practical considerations in ovarian cancer chemotherapy","volume":"2","author":"Cristea","year":"2010","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106329_bib60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a gynecologic oncology group study","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.phrs.2022.106329_bib61","series-title":"Intraperitoneal Therapy for Ovarian Cancer","author":"Alberts","year":"2010"},{"issue":"Suppl. 15","key":"10.1016\/j.phrs.2022.106329_bib62","article-title":"Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma","volume":"38","author":"Annunziata","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2022.106329_bib63","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","article-title":"A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer","volume":"13","author":"Koneru","year":"2015","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.phrs.2022.106329_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20599-x","article-title":"Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma","volume":"12","author":"Agliardi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2022.106329_bib65","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2020.06.089","article-title":"A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC)","volume":"159","author":"O\u2019Cearbhaill","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.phrs.2022.106329_bib66","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fonc.2019.00069","article-title":"Next generation CAR T cells for the immunotherapy of high-grade glioma","volume":"9","author":"Petersen","year":"2019","journal-title":"Front. Oncol."},{"issue":"Suppl. 16","key":"10.1016\/j.phrs.2022.106329_bib67","article-title":"Abstract 6593: PRGN-3005 UltraCAR-TTM: multigenic CAR-T cells generated using non-viral gene delivery and rapid manufacturing process for the treatment of ovarian cancer","volume":"80","author":"Chan","year":"2020","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.phrs.2022.106329_bib68","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/JTO.0b013e31820d614f","article-title":"Palliation and pleurodesis in malignant pleural effusion: the role for tunneled pleural catheters","volume":"6","author":"Suzuki","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2022.106329_bib69","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1378\/chest.06-2353","article-title":"Catheter-tract metastases associated with chronic indwelling pleural catheters","volume":"131","author":"Janes","year":"2007","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.phrs.2022.106329_bib70","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1183\/09031936.00164706","article-title":"Use of tunnelled catheters for malignant pleural effusions in patients fit for pleurodesis","volume":"30","author":"Tremblay","year":"2007","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.phrs.2022.106329_bib71","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/crj.13010","article-title":"Intrapleural immunotherapy: an update on emerging treatment strategies for pleural malignancy","volume":"13","author":"Murthy","year":"2019","journal-title":"Clin. Respir. J."},{"key":"10.1016\/j.phrs.2022.106329_bib72","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3389\/fonc.2020.00777","article-title":"Cellular immunotherapy and locoregional administration of CAR T-cells in malignant pleural mesothelioma","volume":"10","author":"Belderbos","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2022.106329_bib73","first-page":"30","article-title":"A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells","author":"Curioni","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2022.106329_bib74","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1186\/1471-2407-12-615","article-title":"Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)","volume":"12","author":"Petrausch","year":"2012","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.phrs.2022.106329_bib75","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2022.106329_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2022.01.003","article-title":"Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I\/II clinical trial","volume":"165","author":"Ghosn","year":"2022","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2022.106329_bib77","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001800","article-title":"Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy","volume":"9","author":"Munoz","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.phrs.2022.106329_bib78","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.7911","article-title":"Assessment of image-guided intratumoral delivery of immunotherapeutics in patients with cancer","volume":"3","author":"Sheth","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"11","key":"10.1016\/j.phrs.2022.106329_bib79","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1093\/annonc\/mdy423","article-title":"Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)","volume":"29","author":"Marabelle","year":"2018","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106329_bib80","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.gie.2016.11.014","article-title":"EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer","volume":"86","author":"Levy","year":"2016","journal-title":"Gastrointest. Endosc."},{"issue":"4","key":"10.1016\/j.phrs.2022.106329_bib81","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1067\/mge.2001.112839","article-title":"Assessment of complications of EUS-guided fine-needle aspiration","volume":"53","author":"O\u2019Toole","year":"2001","journal-title":"Gastrointest. Endosc."},{"issue":"9","key":"10.1016\/j.phrs.2022.106329_bib82","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/14712598.2020.1786531","article-title":"PanErbB-targeted CAR T-cell immunotherapy of head and neck cancer","volume":"20","author":"Larcombe-Young","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2022.106329_bib83","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/humc.2013.144","article-title":"Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer","volume":"24","author":"van Schalkwyk","year":"2013","journal-title":"Hum. Gene Ther. Clin. Dev."},{"issue":"12","key":"10.1016\/j.phrs.2022.106329_bib84","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.phrs.2022.106329_bib85","doi-asserted-by":"crossref","first-page":"665230","DOI":"10.3389\/fimmu.2021.665230","article-title":"Case report: combined intravenous infusion and local injection of CAR-T cells induced remission in a relapsed diffuse large B-cell lymphoma patient","volume":"12","author":"Hu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2022.106329_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112512","article-title":"Therapeutic potential of CAR T cell in malignancies: a scoping review","volume":"146","author":"Mehrabadi","year":"2022","journal-title":"Biomed. Pharmacother."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822002742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822002742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:40:48Z","timestamp":1760913648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822002742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":86,"alternative-id":["S1043661822002742"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106329","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Locoregional delivery of CAR-T cells in the clinic","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106329","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106329"}}